Flamingo Therapeutics NV
Latest round
- Series A
Last raised
- Jul 2021
Total raised
- Undisclosed
Investors
- 2
About Flamingo Therapeutics NV
Based in Belgium, and founded in 2020, Flamingo Therapeutics NV operates as an RNA (ribonucleic acid) therapeutics company. The company was founded by VIB, Ghent University, KU Leuven, the University of Michigan, Kurma Partners, and PMV. In March 2023, Dynacure SA, a portfolio company of Andera Partners, CDC Enterprises, Perceptive Advisors, and Tekla Capital Management, agreed to merge with Flamingo Therapeutics and will continue to operate under the Flamingo Therapeutics brand. As of 2023, the company’s president and CEO is Stéphane van Rooijen. Flamingo Therapeutics offers a drug development platform, which is a biotech platform that develops RNA-based therapeutics for cancer patients. The company’s pipeline programs include Danvatirsen, a drug that targets STAT-3, and FTX-001, a drug that targets MALAT1. In addition, the company provides FLAME (Flamingo LncRNA Antisense Mining Engine), which is a long non-coding RNA platform that develops drugs for diseases like cancer.
Who invested in Flamingo Therapeutics NV
2 investors across 1 round
See all investors in Flamingo Therapeutics NV
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jul 1, 2021
Amount
Undisclosed
Investors
Questions about Flamingo Therapeutics NV
Who invested in Flamingo Therapeutics NV?
Flamingo Therapeutics NV has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Flamingo Therapeutics NV raised?
Flamingo Therapeutics NV has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Flamingo Therapeutics NV last raise money?
Flamingo Therapeutics NV's most recent round on record is a Series A, in Jul 2021.
What does Flamingo Therapeutics NV do?
Based in Belgium, and founded in 2020, Flamingo Therapeutics NV operates as an RNA (ribonucleic acid) therapeutics company.
Where is Flamingo Therapeutics NV headquartered?
Flamingo Therapeutics NV is headquartered in Leuven, Belgium.
Which VCs invest in companies like Flamingo Therapeutics NV?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Flamingo Therapeutics NV's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Flamingo Therapeutics NV? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.